Tethis Acquires See.d Platform from MACS, Taps Everex to Scale Production
Milan – September 21, 2026 -- Tethis S.p.A. has completed the acquisition of the See.d software and engineering business unit from MACS S.r.l., gaining full control over intellectual property and engineering know-how behind its liquid biopsy platform. Alongside the transfer, Tethis signed a long-term manufacturing and supply agreement with Everex S.r.l., an Italian in-vitro diagnostic instrumentation maker, to handle production and future scale-up of the system.
Tethis consolidates full ownership of its liquid biopsy pre-analytical platform
See.d is the cornerstone of Tethis' liquid biopsy workflow, developed jointly with MACS to standardize pre-analytical blood processing. From a single blood sample, the platform generates plasma for cfDNA analysis and cytology slides preserving nucleated cells for downstream characterization, automating plasma separation, red blood cell lysis, and deposition onto Tethis' proprietary SmartBioSurface slides.